Literature DB >> 18298903

Expression of PLK1 and survivin in non-Hodgkin's lymphoma treated with CHOP.

Lin Liu1, Min Zhang, Ping Zou.   

Abstract

AIM: The present study was designed to investigate the expression of Polo-like kinase 1 (PLK1) and survivin in non-Hodgkinos lymphoma (NHL).
METHODS: The expression of PLK1 and survivin were detected with immunohistochemical techniques.
RESULTS: The expression rate of PLK1 and survivin were 63.6% (56/88) and 79.5% (70/88) in NHL, respectively. PLK1 expression correlated with systemic symptoms, lactate dehydrogenase levels, and international prognostic index scores in B-NHL and T-NHL, while survivin did not.
CONCLUSION: PLK1 and survivin are both overexpressed in NHL. There is a significant relationship between the overexpression of PLK1 and clinical features.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18298903     DOI: 10.1111/j.1745-7254.2008.00750.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  6 in total

1.  Specific survivin dual fluorescence resonance energy transfer molecular beacons for detection of human bladder cancer cells.

Authors:  Zhi-qiang Wang; Jun Zhao; Jin Zeng; Kai-jie Wu; Yu-le Chen; Xin-yang Wang; Luke S Chang; Da-lin He
Journal:  Acta Pharmacol Sin       Date:  2011-10-24       Impact factor: 6.150

Review 2.  Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.

Authors:  Ion Cristóbal; Federico Rojo; Juan Madoz-Gúrpide; Jesús García-Foncillas
Journal:  Mol Cell Biol       Date:  2016-05-31       Impact factor: 4.272

3.  Identification of polo-like kinase 1 as a therapeutic target in murine lupus.

Authors:  Yaxi Li; Hongting Wang; Zijing Zhang; Chenling Tang; Xinjin Zhou; Chandra Mohan; Tianfu Wu
Journal:  Clin Transl Immunology       Date:  2022-01-06

4.  Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma.

Authors:  Tomonori Higuchi; Yumiko Hashida; Ayuko Taniguchi; Mikio Kamioka; Masanori Daibata
Journal:  Sci Rep       Date:  2017-09-08       Impact factor: 4.379

5.  BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.

Authors:  Er Chen; Renzhi Pei
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

6.  Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4+ T cells ex vivo.

Authors:  Dawei Zhou; Tsuyoshi Hayashi; Maxime Jean; Weili Kong; Guillaume Fiches; Ayan Biswas; Shuai Liu; Hailemichael O Yosief; Xiaofeng Zhang; Jay Bradner; Jun Qi; Wei Zhang; Netty Santoso; Jian Zhu
Journal:  Sci Adv       Date:  2020-07-15       Impact factor: 14.136

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.